Envestnet Asset Management Inc. Has $2.67 Million Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Envestnet Asset Management Inc. lifted its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPNGet Rating) by 8.7% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 78,904 shares of the specialty pharmaceutical company’s stock after acquiring an additional 6,284 shares during the period. Envestnet Asset Management Inc. owned approximately 0.15% of Supernus Pharmaceuticals worth $2,671,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of SUPN. Vanguard Group Inc. lifted its position in Supernus Pharmaceuticals by 0.5% during the first quarter. Vanguard Group Inc. now owns 5,538,820 shares of the specialty pharmaceutical company’s stock worth $179,015,000 after purchasing an additional 25,671 shares during the period. Polaris Capital Management LLC lifted its position in Supernus Pharmaceuticals by 8,769.9% during the second quarter. Polaris Capital Management LLC now owns 2,918,196 shares of the specialty pharmaceutical company’s stock worth $45,611,000 after purchasing an additional 2,885,296 shares during the period. Macquarie Group Ltd. lifted its position in Supernus Pharmaceuticals by 0.7% during the second quarter. Macquarie Group Ltd. now owns 2,337,304 shares of the specialty pharmaceutical company’s stock worth $67,595,000 after purchasing an additional 17,354 shares during the period. Dimensional Fund Advisors LP lifted its position in Supernus Pharmaceuticals by 1.4% during the third quarter. Dimensional Fund Advisors LP now owns 2,270,480 shares of the specialty pharmaceutical company’s stock worth $76,854,000 after purchasing an additional 31,355 shares during the period. Finally, Renaissance Technologies LLC lifted its position in Supernus Pharmaceuticals by 12.3% during the second quarter. Renaissance Technologies LLC now owns 1,397,022 shares of the specialty pharmaceutical company’s stock worth $40,402,000 after purchasing an additional 153,500 shares during the period. 99.82% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on SUPN shares. StockNews.com cut shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday. TheStreet raised shares of Supernus Pharmaceuticals from a “c+” rating to a “b+” rating in a report on Tuesday, February 28th. Finally, Piper Sandler increased their target price on shares of Supernus Pharmaceuticals from $40.00 to $47.00 and gave the stock an “overweight” rating in a report on Monday, January 23rd.

Supernus Pharmaceuticals Trading Down 0.1 %

SUPN stock opened at $38.36 on Wednesday. The stock has a market capitalization of $2.07 billion, a P/E ratio of 37.24 and a beta of 1.01. Supernus Pharmaceuticals, Inc. has a 12 month low of $24.95 and a 12 month high of $42.09. The firm has a 50-day moving average price of $39.19 and a 200-day moving average price of $36.20.

Supernus Pharmaceuticals (NASDAQ:SUPNGet Rating) last posted its earnings results on Tuesday, February 28th. The specialty pharmaceutical company reported $0.43 EPS for the quarter, missing analysts’ consensus estimates of $0.73 by ($0.30). The company had revenue of $167.33 million during the quarter, compared to the consensus estimate of $180.38 million. Supernus Pharmaceuticals had a return on equity of 7.12% and a net margin of 9.10%. The firm’s revenue was up 5.2% compared to the same quarter last year. During the same period last year, the company posted $0.04 EPS. As a group, equities analysts predict that Supernus Pharmaceuticals, Inc. will post 0.66 EPS for the current fiscal year.

Insider Activity at Supernus Pharmaceuticals

In related news, CEO Jack A. Khattar sold 11,354 shares of the firm’s stock in a transaction that occurred on Wednesday, December 21st. The shares were sold at an average price of $38.14, for a total value of $433,041.56. Following the completion of the transaction, the chief executive officer now owns 814,699 shares in the company, valued at approximately $31,072,619.86. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, CEO Jack A. Khattar sold 13,532 shares of the firm’s stock in a transaction that occurred on Thursday, February 2nd. The shares were sold at an average price of $42.05, for a total value of $569,020.60. Following the completion of the transaction, the chief executive officer now owns 804,142 shares in the company, valued at approximately $33,814,171.10. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Jack A. Khattar sold 11,354 shares of the firm’s stock in a transaction that occurred on Wednesday, December 21st. The shares were sold at an average price of $38.14, for a total transaction of $433,041.56. Following the completion of the transaction, the chief executive officer now owns 814,699 shares of the company’s stock, valued at approximately $31,072,619.86. The disclosure for this sale can be found here. Insiders sold a total of 56,308 shares of company stock worth $2,261,264 in the last quarter. 8.70% of the stock is owned by insiders.

Supernus Pharmaceuticals Company Profile

(Get Rating)

Supernus Pharmaceuticals, Inc engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.

Further Reading

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.